ALSO NOTED: BioCryst raises $65M; FDA approves Sanctura XR; and much more...

> BioCryst Pharmaceuticals has announced a $65 million private placement. Release

> The FDA has provided its approval for Indevus' Sanctura XR, the once-daily formulation of its therapy for overactive bladder. Release

> Thrilling AIDS activists and frustrating the drug company, an Indian court rejected Novartis' challenge to its drug patent laws. FiercePharma

> Patients who once dependent on Vioxx for arthritis relief are still lobbying Merck to get the drug back on the market--despite the documented risk of heart attacks, strokes, even death. FiercePharma

And Finally… Scientists have found that even left-handedness has a genetic link. Report

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.